Iovance Biotherapeutics Inc. (IOVA)

13.55
NASDAQ : Health Technology
Prev Close 13.65
Day Low/High 13.35 / 13.93
52 Wk Low/High 6.60 / 19.90
Avg Volume 1.09M
Exchange NASDAQ
Shares Outstanding 95.59M
Market Cap 1.30B
EPS -1.40
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

How to Handle the Fed: Cramer's 'Mad Money' Recap (Wednesday 6/13/18)

How to Handle the Fed: Cramer's 'Mad Money' Recap (Wednesday 6/13/18)

Jim Cramer says higher rates always trigger rotations. Here's what investors should expect.

First Week Of IOVA July 20th Options Trading

First Week Of IOVA July 20th Options Trading

Investors in Iovance Biotherapeutics Inc saw new options begin trading this week, for the July 20th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the IOVA options chain for the new July 20th contracts and identified the following call contract of particular interest.

Small-Cap Stocks Lead the Way

Small-Cap Stocks Lead the Way

As interest rate fears ease slightly, indexes rebound.

4 Small Speculative Names on My Radar

4 Small Speculative Names on My Radar

While I'm waiting for some index excitement I'm focused on trades in individual stocks.

Lennar Is One of 6 Stocks Poised to Change Direction

Lennar Is One of 6 Stocks Poised to Change Direction

These names are showing technical characteristics of either bullish or bearish reversal patterns over the past week.

Iovance Biotherapeutics Reports Fourth Quarter And Full-Year 2017 Financial Results And Provides Corporate Update

Iovance Biotherapeutics Reports Fourth Quarter And Full-Year 2017 Financial Results And Provides Corporate Update

Company to Host Conference Call at 4:30pm ET Today

Iovance Biotherapeutics Appoints Michael Weiser, M.D., Ph.D., To Its Board Of Directors

Iovance Biotherapeutics Appoints Michael Weiser, M.D., Ph.D., To Its Board Of Directors

Industry Veteran Brings Significant Clinical, Commercial, and Business Experience

Sound Familiar? Dovish Fed Talk Induces Stock Reversal

Sound Familiar? Dovish Fed Talk Induces Stock Reversal

The market's reaction to James Bullard's comments this morning is following an all-too-common pattern.

Biotech Gold Rush Starts to Pick Up; Xerox, Fujifilm Saga Continues -- ICYMI

Biotech Gold Rush Starts to Pick Up; Xerox, Fujifilm Saga Continues -- ICYMI

Here's what you need to know now for Wednesday, Feb. 14.

Biotech Heats Up as Fear of Missing Out Returns

Biotech Heats Up as Fear of Missing Out Returns

It's hard to believe the bounce will continue to run in V-shaped fashion.

Focused on Two Sectors

Focused on Two Sectors

If we have a little consolidating action here the buyers will start pushing again.

5 Top Stocks With 100% Buy Ratings Right Now

5 Top Stocks With 100% Buy Ratings Right Now

These five 'Strong Buy' stocks boast a double whammy of only buy ratings and big upside potential. After the market's recent plunge, this list is quite handy.

Markets Face Heavy News Flow in Next 48 Hours

Markets Face Heavy News Flow in Next 48 Hours

In addition to the State of the Union address and the Fed interest rate decision, companies representing about 25% of the Nasdaq 100's market cap will report results in the next two days.

'Normal' Market Selloff Feels Much Worse Than It Really Is

'Normal' Market Selloff Feels Much Worse Than It Really Is

While painful to longs, the market will be better for it.

This Market Badly Needs a Rest

This Market Badly Needs a Rest

It would be a longer-term positive if the overbought conditions are alleviated.

Building in Biotech, Adding to Twitter

Building in Biotech, Adding to Twitter

The challenge of this market is to keep finding new buy entries as more and more stocks become extended.

Market Gets a Little Bumpy, but Stock-Picking Still Rocks

Market Gets a Little Bumpy, but Stock-Picking Still Rocks

Only when the picking worsens will I start to worry.

Biotech Looks Good and I'm Buying

Biotech Looks Good and I'm Buying

The sector has been a great trading group lately and I bought these 2 names this morning.

In This Booming Stock Market, Think Like a Programmer Not a Critic

In This Booming Stock Market, Think Like a Programmer Not a Critic

What drives the trading action are structural issues, not macroeconomic news events or political drama.